Business Description
Anika Therapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US0352551081
Share Class Description:
STU:AKP: Ordinary SharesTotal Employee Number:
235Description
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.52 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | 49.32 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 5.28 | |||||
Beneish M-Score | -2.67 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.7 | |||||
3-Year Book Growth Rate | -19.1 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 121.03 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.74 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 87.96 | |||||
9-Day RSI | 83.53 | |||||
14-Day RSI | 78.37 | |||||
3-1 Month Momentum % | 7.81 | |||||
6-1 Month Momentum % | 55.93 | |||||
12-1 Month Momentum % | 97.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.48 | |||||
Quick Ratio | 3.19 | |||||
Cash Ratio | 1.73 | |||||
Days Inventory | 165.34 | |||||
Days Sales Outstanding | 75.42 | |||||
Days Payable | 44.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.7 | |||||
Shareholder Yield % | 3.52 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 62.17 | |||||
Operating Margin % | -4.24 | |||||
Net Margin % | -3.14 | |||||
EBITDA Margin % | 0.42 | |||||
FCF Margin % | 0.36 | |||||
OCF Margin % | 4.84 | |||||
ROE % | -2.67 | |||||
ROA % | -2.03 | |||||
ROIC % | -4 | |||||
3-Year ROIIC % | 10.4 | |||||
ROC (Joel Greenblatt) % | -5.27 | |||||
ROCE % | -3.08 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 185.19 | |||||
PE Ratio without NRI | 24.91 | |||||
PS Ratio | 2.48 | |||||
PB Ratio | 2.09 | |||||
Price-to-Tangible-Book | 2.24 | |||||
Price-to-Free-Cash-Flow | 4284 | |||||
Price-to-Operating-Cash-Flow | 54.5 | |||||
EV-to-EBIT | -53.41 | |||||
EV-to-Forward-EBIT | 48.44 | |||||
EV-to-EBITDA | 534.18 | |||||
EV-to-Forward-EBITDA | 39.52 | |||||
EV-to-Revenue | 2.27 | |||||
EV-to-Forward-Revenue | 2.23 | |||||
EV-to-FCF | 486.66 | |||||
Price-to-GF-Value | 1.1 | |||||
Price-to-Projected-FCF | 2.79 | |||||
Price-to-Median-PS-Value | 0.62 | |||||
Price-to-Graham-Number | 1.58 | |||||
| Price-to-Net-Current-Asset-Value | 5.41 | |||||
Earnings Yield (Greenblatt) % | -1.87 | |||||
FCF Yield % | 0.2 | |||||
Forward Rate of Return (Yacktman) % | -9.4 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anika Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 103.764 | ||
| EPS (TTM) (€) | -0.231 | ||
| Beta | 0.0272 | ||
| 3-Year Sharpe Ratio | -0.01 | ||
| 3-Year Sortino Ratio | -0.01 | ||
| Volatility % | 55.18 | ||
| 14-Day RSI | 78.37 | ||
| 14-Day ATR (€) | 1.116443 | ||
| 20-Day SMA (€) | 14.585 | ||
| 12-1 Month Momentum % | 97.14 | ||
| 52-Week Range (€) | 6.9 - 18.3 | ||
| Shares Outstanding (Mil) | 13.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anika Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anika Therapeutics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-05 08:30 | In 88 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 87 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | 13.20 (-1.49%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 13.20 (-1.49%) | ||
| General meeting for 2026 | 2026-06-18 08:30 | 12.30 (+2.50%) | ||
| First quarter earnings conference call for 2026 | 2026-04-29 08:30 | 13.10 (-2.24%) | ||
| First quarter earnings results for 2026 | 2026-04-29 | 13.10 (-2.24%) | ||
| Annual report for 2025 | 2026-03-03 | 12.20 (+1.67%) | ||
| Guidance call for 2026 | 2026-03-02 12:30 | 10.90 (+3.81%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-02-26 08:30 | 9.20 (+1.66%) |
Show
Entries
Anika Therapeutics Inc Frequently Asked Questions
What is Anika Therapeutics Inc(STU:AKP)'s stock price today?
The current price of STU:AKP is €18.30. The 52 week high of STU:AKP is €18.30 and 52 week low is €6.90.
When is next earnings date of Anika Therapeutics Inc(STU:AKP)?
The next earnings date of Anika Therapeutics Inc(STU:AKP) is 2026-11-05 Est..
Does Anika Therapeutics Inc(STU:AKP) pay dividends? If so, how much?
Anika Therapeutics Inc(STU:AKP) does not pay dividend.
Press Release
Articles on Anika Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers